Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MC4R | P32245 | 1/20 | 0.66 |
| ▸ | CHKA | P35790 | 6/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | NCF1 | P14598 | 1/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82686 | 0.82 | LMNA (0.71) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL2056138 | 0.82 | LMNA (0.69) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL306744 | 0.82 | LMNA (0.69) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL302270 | 0.81 | HRH3 (0.74) | NCF1ALDH1A1KDM4EHRH3 | |
| SCHEMBL1507008 | 0.80 | LMNA (0.67) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL6072982 | 0.80 | LMNA (0.67) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL578497 | 0.80 | LMNA (0.67) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL21477255 | 0.80 | LMNA (0.67) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL55983 | 0.80 | LMNA (1.00) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL3451622 | 0.80 | LMNA (0.67) | LMNAMC4RCHKACA2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021109944-A1 | WEAK ALKALINE CABAZITAXEL DERIVATIVE AND FORMULATION THEREOF | 沈阳药科大学 | 2021-06-10 | — | — | WO | claimed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | claimed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| EP-3455227-A1 | OXABOROLE ESTERS AND USES THEREOF | Anacor Pharmaceuticals, Inc (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017195069-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| CN-100384418-C | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| CN-1635889-A | Isoxazolopyridinones and their use in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2005-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | LMNA 2067/4885MC4R 541/4885CHKA 2114/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | LMNA 2067/4885MC4R 541/4885CHKA 2114/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | LMNA 2067/4885MC4R 541/4885CHKA 2114/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | LMNA 2067/4885MC4R 541/4885CHKA 2114/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | LMNA 2067/4885MC4R 541/4885CHKA 2114/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | LMNA 2067/4885MC4R 541/4885CHKA 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.